中期因子在不同分子分型的乳腺癌中的表达及其临床意义  

Expression and clinical significance of midkine in breast carcinomas with different immunohistochemical profiling

作　　者：闵丽姗[1,2] 陈莹蓉[2] 马志红[2] 戴利成[2] 王青青[1] 

机构地区：[1]浙江大学医学院免疫学研究所,杭州310058 [2]湖州市中心医院,湖州市分子医学重点实验室,湖州313000

出　　处：《现代免疫学》2012年第5期381-386,共6页Current Immunology

基　　金：湖州市科技项目(2011YS04)

摘　　要：探讨在5种不同分子分型的乳腺癌中中期因子在组织中的表达,并分析其临床意义。采用免疫组化法检测203例乳腺癌组织的中期因子表达量;采用CD105抗体标记微血管内皮细胞,计算微血管密度(MVD)。结果显示,中期因子与肿瘤的淋巴结转移、临床分期相关性密切。中期因子表达量高的样本具有较高的以CD105表征的微血管密度。与其他4种分子分型相比,中期因子和CD105在基底细胞样型的表达量最高,但是该差异不具有统计学意义。中期因子可以作为乳腺癌预后的标记物应用于临床诊断和治疗,与其他分子亚型的乳腺癌相比,基底细胞样型的乳腺癌可能并不具有独特的血管生成模式。To investigate the expression of midkine and endoglin in breast carcinomas with 5 different immunohistochemical pro filing and their relevance to clinicopathologic features, the expression of midkine was detected by immunohistochemistry （IHC） in the tissues from 203 breast carcinomas patients. The microvessel density （MVD） was determined by endoglin （CD105） im munostaining of microvascular endothelial cells. The higher expression of midkine in breast cancer significantly correlated with lymph node metastasis and TNM staging. The MVD count was higher in high midkine reactivity group than in negative/low midkine reactivity group. Although the basallike subtype had higher midkine expression level and MVD, there were no signifi cant differences from the other subtypes of breast cancer. MK is a promising target for tumor prognosis in clinical diagnose and treatment. This study finds no significant differeces in tumor angiogenesis between different molecular subtypes of breast canc

关 键 词：基底样亚型 乳腺癌 中期因子 血管内皮素 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]